Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This was a cross-over, polysomnography (PSG) study to test the safety, tolerability and
effectiveness of different doses of MK-6096 in the treatment of participants with primary
insomnia. The primary efficacy hypothesis was that at least one dose of MK-6096 is superior
to placebo in improving sleep efficiency (SE) as measured by PSG on Night 1 and at the end of
4 weeks of treatment (Week 4).